NEW YORK, Jan 3, 2026, 14:19 ET — Market closed
- Johnson & Johnson declared a $1.30 quarterly cash dividend, payable March 10; record and ex-dividend date is Feb. 24.
- JNJ shares closed Friday up $0.39, or 0.2%, at $207.35.
- Attention shifts to the Jan. 21 fourth-quarter earnings call and the broader direction of interest rates.
Johnson & Johnson said its board declared a quarterly cash dividend of $1.30 per share for the first quarter of 2026. JNJ shares closed Friday up $0.39, or 0.2%, at $207.35, with the ex-dividend date — the cutoff after which new buyers do not receive the payout — set for Feb. 24.
The announcement matters for income-focused holders because it locks in the next set of dates for a widely held blue-chip name at the start of a new year. It also puts a fresh spotlight on “total return” — price performance plus dividends — as investors reset portfolios in January.
Johnson & Johnson is often treated as a defensive healthcare holding because demand for medicines and medical devices tends to be less tied to the economic cycle than consumer spending. In that setup, shifts in yields and risk appetite can matter as much as company headlines.
U.S. stocks ended mixed on Friday in light post-holiday trading, with the Dow up 0.66% and the S&P 500 up 0.19%, while the Nasdaq slipped 0.03%. “Value is outperforming growth and AI infrastructure is up,” said Jed Ellerbroek, portfolio manager at Argent Capital, as the benchmark U.S. 10-year Treasury yield finished around 4.19%. Reuters
The company highlights a long dividend-growth record, saying it has delivered more than 60 consecutive years of dividend increases.
Annualized, the new quarterly payout implies $5.20 per share a year, or about a 2.5% yield based on Friday’s close. That yield math is one reason the stock is frequently grouped with other large-cap “income defensives.”
Other big drugmakers also ended higher on Friday, with Pfizer up 1.1%, Merck up 1.2% and AbbVie up 0.4%.
Before the next U.S. session on Monday, Jan. 5, investors will look ahead to Johnson & Johnson’s fourth-quarter earnings call and webcast on Jan. 21 at 8:30 a.m. ET, according to the company’s investor calendar.
That call is the next scheduled catalyst for the stock, with investors typically drilling into prescription-drug demand, medical-device trends and any shifts in spending priorities. The tone around capital returns — how dividends fit alongside investment and other uses of cash — is also a common focus for long-term holders.
From a chart perspective, the $200 area is a near-term reference point traders watch. MarketBeat data put JNJ’s 50-day moving average around $200.83 and its 200-day average around $182.27.
The next dividend milestone is Feb. 24, when the stock goes ex-dividend, followed by the March 10 payment. Until earnings season takes center stage later this month, JNJ’s day-to-day moves are likely to stay closely tied to rates and the market’s broader preference for value versus growth.
